Related Subjects:
|Alpha Thalassaemia
|Beta Thalassaemia
|Anaemia of Chronic Disease
|Aplastic anaemia(AML)
|Autoimmune Haemolytic anaemia (AIHA)
Beta Thalassaemia Trait (Minor) is a common, inherited haemoglobinopathy characterized by a mild, asymptomatic hypochromic microcytic anaemia. It is caused by a heterozygous mutation in the beta-globin gene. The hallmark diagnostic feature is an increased level of HbA&sub2; on haemoglobin electrophoresis.
ℹ️ About & Genetics
- Genetic Basis: Beta Thalassaemia is an autosomal recessive condition caused by mutations in the β-globin gene (HBB) on chromosome 11.
- Inheritance: Inheriting one mutated gene results in Beta Thalassaemia Trait (carrier state/Minor). Inheriting two mutated genes results in Thalassaemia Major or Intermedia.
- Haemoglobin Composition: Normal adult haemoglobin (HbA) is composed of two α (alpha) and two β (beta) chains (α&sub2;β&sub2;). Beta Thalassaemia results from reduced (β⊎) or absent (βº) production of β-globin chains.
- Compensatory Mechanisms: To compensate for the lack of HbA, the body slightly increases the production of HbA&sub2; (α&sub2;δ&sub2;) and sometimes fetal haemoglobin (HbF, α&sub2;γ&sub2;).
🌍 Epidemiology
- Prevalence: Most prevalent in individuals of Mediterranean (e.g., Italian, Greek, Cypriot), Middle Eastern, South Asian, and Southeast Asian descent.
- Malaria Hypothesis: The high carrier frequency in these regions is due to a historical heterozygous advantage, providing partial protection against Plasmodium falciparum malaria.
🗂️ Classification of Beta Thalassaemia
- Thalassaemia Minor (Trait):
- Genetics: Heterozygous (one mutated HBB gene).
- Clinical: Clinically asymptomatic, mild microcytic anaemia. Discovered incidentally.
- Thalassaemia Intermedia:
- Genetics: Mild homozygous or compound heterozygous mutations.
- Clinical: Moderate anaemia, splenomegaly, bone deformities. May require occasional transfusions (non-transfusion dependent thalassaemia - NTDT).
- Thalassaemia Major (Cooley's Anaemia):
- Genetics: Homozygous or compound heterozygous (severe mutations).
- Clinical: Severe, life-threatening anaemia presenting in the first year of life. Requires lifelong regular blood transfusions.
- Complications: Transfusional iron overload leading to cardiomyopathy, liver cirrhosis, and endocrine failure. Extramedullary haemopoiesis causes hepatosplenomegaly and skeletal deformities ("hair-on-end" skull X-ray).
🩺 Clinical Features (Beta Thalassaemia Trait)
- Mostly Asymptomatic: The vast majority of carriers have no symptoms and lead completely normal lives.
- Incidental Finding: Usually picked up on a routine Full Blood Count (FBC) or during antenatal screening.
- Physiological Stress: May experience mild fatigue or worsening of anaemia during periods of stress, such as pregnancy or severe infection.
🔎 Investigations & Diagnosis
- Full Blood Count (FBC):
- Mild anaemia (Hb usually 90–110 g/L).
- Disproportionately low Mean Corpuscular Volume (MCV < 75 fL) and Mean Corpuscular Haemoglobin (MCH < 27 pg) relative to the degree of anaemia.
- Elevated Red Blood Cell count (RBC > 5.0 × 10¹²/L) – a key differentiator from iron deficiency.
- Mentzer Index: MCV / RBC count. A ratio < 13 strongly suggests Thalassaemia Trait, whereas > 13 suggests Iron Deficiency Anaemia.
- Blood Film: Microcytosis, hypochromia, target cells, and basophilic stippling.
- Haemoglobinopathy Screen (Electrophoresis / HPLC):
- Raised HbA&sub2;: Typically > 3.5% (Diagnostic for Beta Thalassaemia Trait).
- HbF may be slightly elevated (1–5%).
- Iron Studies: Serum ferritin and iron are normal. It is crucial to check this to avoid misdiagnosing as iron deficiency.
💊 Management
- Management of Thalassaemia Trait (Minor):
- Reassurance: No medical treatment or regular follow-up is required.
- Avoid Inappropriate Iron: Do not prescribe iron supplements for the microcytic anaemia unless a concurrent iron deficiency is proven (e.g., low ferritin).
- Genetic Counselling & Family Planning: This is the most important intervention. If both parents are carriers, there is a 25% chance of having a child with Thalassaemia Major.
- Antenatal Screening: Offered to all pregnant women in the UK to identify carriers early and offer partner testing.
- Management of Thalassaemia Major (Brief Overview):
- Lifelong regular red blood cell transfusions (aiming for pre-transfusion Hb 95–105 g/L).
- Iron chelation therapy (e.g., deferasirox, deferoxamine) to prevent fatal iron overload.
- Multidisciplinary monitoring for endocrine, cardiac, and hepatic complications.
- Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative option.
🏁 Prognosis
- Thalassaemia Minor (Trait): Excellent prognosis. Carriers lead normal, healthy lives with a normal life expectancy.
- Thalassaemia Major: Historically fatal in childhood, but modern transfusion and chelation protocols allow patients to survive well into adulthood, though morbidity from iron overload remains a challenge.
🧑⚕️ Case Examples - Beta Thalassaemia Trait
-
Case 1 (Incidental finding in pregnancy): 🤰
A 28-year-old pregnant woman of Greek descent has her booking bloods taken at 10 weeks gestation. She is asymptomatic. FBC shows Hb 105 g/L, MCV 68 fL, MCH 22 pg. Ferritin is normal. Haemoglobin electrophoresis shows HbA&sub2; of 5.2%.
Diagnosis: Beta Thalassaemia Trait.
Management: Reassurance. Urgent screening of the father of the baby. If the father is also a carrier, refer for specialist fetal medicine counselling and offer prenatal diagnosis (CVS or amniocentesis).
-
Case 2 (Misdiagnosed Iron Deficiency): 💊
A 35-year-old man of Indian descent is referred for "refractory iron deficiency anaemia". He has been taking oral iron for 6 months with no change in his bloods. FBC: Hb 112 g/L, MCV 65 fL, RBC 5.8 × 10¹²/L. Mentzer index is 11.2. Iron studies show a ferritin of 450 μg/L (high-normal).
Diagnosis: Beta Thalassaemia Trait (incorrectly treated as iron deficiency).
Management: Stop iron supplementation to prevent iron overload. Perform Hb electrophoresis to confirm the diagnosis.
📋 References & UK Guidelines
